BioSpace News Archive

Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced three internally developed investigational preclinical gene therapy product candidates from its ophthalmology program.

Biogen Inc. (NASDAQ: BIIB) today announced the appointment of Chuck Triano as Senior Vice President, Head of Investor Relations effective 10 April 2023.

Agenus Inc. (Nasdaq: AGEN), an immuno-oncology company with a pipeline of immunological agents targeting cancer and infectious disease, today provided a corporate update and reported financial results for the fourth quarter and full year 2022.

Biohaven Ltd. (NYSE: BHVN) announced today that it will present an oral and poster presentation demonstrating the preclinical efficacy and initial Phase 1 safety and tolerability of BHV-7000.

Enveric Biosciences announced today new research detailing the first-ever isolation of a novel indolethylamine N -methyltran from cane toad (Rhinella marina) and the successful development of a bioproduction platform for the isolation and pharmacological screening of novel indolethylamines.

Bormioli Pharma today announced robust growth in its North American business in 2022, with sales increasing more than 40% year-over-year.

Ludwig Enterprises, Inc. and its subsidiary Precision Genomics has attracted significant clinical interest in its patent pending mRNA Inflammatory Index which measures inflammatory biomarkers that are associated with chronic diseases such as cancer, diabetes and heart disease.

Cogent Biosciences, Inc. today provided a business update and reported financial results for the fourth quarter and full year of 2022.

Novan, Inc., announced that it has entered into definitive agreements for the issuance and sale in a registered direct offering of an aggregate of 5,042,017 shares of its common stock and warrants to purchase up to 5,042,017 shares of common stock, at an effective combined purchase price of $1.19 per share and associated Common Warrant.

EMulate Therapeutics, Inc. today announced the addition of Donna Morgan Murray, Ph.D. to the Company’s board of directors.